Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stalicla Seals Deal To Advance Novartis Drug For Cocaine Misuse

Seeking The Right Indication For Mavoglurant

Executive Summary

The biotech has persuaded its fellow Swiss firm that it can advance mavoglurant, a Novartis drug that has failed in Parkinson’s and Fragile X syndrome, for cocaine use and neurodevelopmental disorders.

You may also be interested in...

Deal Watch: AbbVie Leads J.P. Morgan Deal Rush, But BI, Genentech And Lilly Also Big Players

As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.

Novartis quietly drops three pipeline projects

Novartis has terminated development of three mid- to late-stage pipeline projects, Scrip discovered after comparing the company's 1Q 2014 and 4Q 2013 results. The dropped products include secukinumab in its uveitis indication, a Phase IIb/III product to treat fragile X syndrome, and a Phase II drug to treat Clostridium difficile infection.

Novartis drops PhII Parkinson's program

Novartis has discontinued development of the investigative compound AFQ056 to treat the jerky motions and tics that are a side-effect of treatment with levodopa in patients with Parkinson's disease. The firm had been planning to file its first regulatory approval submissions in this indication in 2015. However, the product failed to show efficacy in Parkinson's disease levodopa-induced dyskinesia (PD-LID) in recent Phase II studies.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts